REVIEW article
Front. Neurol.
Sec. Sleep Disorders
Comparative Impact of Different Weight Loss Strategies on Obstructive Sleep Apnea: An Integrated Review of Surgical, Pharmacological, and Lifestyle Interventions
Provisionally accepted
Guo-qiang Song*
Guo-qiang Hu*- Changxing County Hospital of Traditional Chinese Medicine, Huzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Obesity is recognized as one of the most significant risk factors for obstructive sleep apnea (OSA), and weight reduction remains an effective strategy for improving OSA symptoms. With the ongoing evolution of bariatric surgery, pharmacological therapies, and conventional weight management approaches such as dietary modification and exercise, there is growing interest in understanding the differential efficacy and mechanisms of these interventions for OSA management. This review systematically examines the impacts of surgical procedures (including bariatric surgeries like gastric sleeve), pharmacological treatments (such as GLP-1 receptor agonists, orlistat, and phentermine/topiramate), and lifestyle-based weight management on OSA outcomes. It analyzes the comparative effectiveness, underlying mechanisms, indications, and limitations of each approach, integrating insights from the latest clinical studies. Additionally, this review discusses the challenges and unresolved issues in the field, such as patient selection, long-term adherence, and the interplay between weight loss and OSA pathophysiology. The purpose of this article is to provide a comprehensive synthesis of current evidence, highlight gaps in knowledge, and outline future directions for integrating weight management strategies into the holistic care of patients with OSA.
Keywords: obstructive sleep apnea, weight reduction, Bariatric Surgery, pharmacological therapy, weight management, GLP-1 receptor agonists
Received: 10 Oct 2025; Accepted: 25 Nov 2025.
Copyright: © 2025 Song and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Guo-qiang Song
Guo-qiang Hu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.